Proteasome Regulation of Interleukin-5 Receptor Endocytosis
Interleukin-5 受体胞吞作用的蛋白酶体调节
基本信息
- 批准号:7731884
- 负责人:
- 金额:$ 30.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-15 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAsthmaBindingBiologicalCell LineCellsClathrinComplexCytoplasmic TailDataDefectDegradation PathwayDevelopmentDominant-Negative MutationDown-RegulationEndocytosisEukaryotaEukaryotic CellEventFigs - dietaryFlow CytometryFunctional disorderGoalsGranulocyte-Macrophage Colony-Stimulating FactorInflammationInflammatoryInterleukin-3Interleukin-5LeucineLigandsMediatingMolecularNatureProtein IsoformsReceptor Down-RegulationReceptor SignalingRegulationRoleSerineSignal TransductionTemperatureTestingTyrosineTyrosine PhosphorylationUbiquitinUbiquitinationatopycytokineenhanced green fluorescent proteinextracellularinterleukin-5 receptormulticatalytic endopeptidase complexmutantnovel strategiesreceptorreceptor internalization
项目摘要
DESCRIPTION (provided by applicant): Interleukin-5 (IL-5) is a hematopoietic cytokine that is central to the pathophysiology of eosinophilic inflammation in atopy and asthma. Understanding mechanisms that extinguish IL-5 receptor (IL-5R)-induced inflammatory signals has importance for the development of novel approaches to modulate IL-5-mediated inflammation. The goal of this application is to define the molecular mechanisms controlling IL-5R internalization by the ubiquitin and proteasome degradation pathway. Our overall hypothesis is that IL-5-induced IL-5R internalization is regulated by two different mechanisms: the ubiquitin/proteasome degradation pathway and clathrin-mediated endocytosis. Aim 1. Test the hypothesis that proteasomes mediate internalization of the ligated IL-5R by first degrading the (c cytoplasmic domain. To determine if degradation of a portion of the (c cytoplasmic domain is the initiating signal for IL-5R internalization, various cytoplasmically truncated (c mutants will be examined for their ability to mediate proteasome-independent internalization of the ligated IL-5R. In addition, requirement for proteasome activity in (c internalization by the other (c engaging cytokines, IL-3 and GM-CSF, will be investigated. Aim 2. Test the hypothesis that the IL-5R is internalized by clathrin-mediated endocytosis and that internalization of the receptor occurs before proteasome degradation of the (c cytoplasmic domain. Two different approaches that inhibit clathrin-mediated endocytosis will be used to determine if the IL-5R is internalized by this mechanism and if IL-5-stimulated (c signaling and proteasome degradation occur after IL-5R internalization. Aim 3. Investigate the functional role and nature of (c ubiquitination in IL-5R internalization. The temperature sensitive ts20 cell line which has a temperature sensitive defect in ubiquitin conjugation, a (c mutant that is defective in all forms of ubiquitination, and dominant negative ubiquitin isoforms will be used to examine the role and nature of (c ubiquitination in IL-5R endocytosis.
描述(由申请人提供):白细胞介素-5 (IL-5)是一种造血细胞因子,在特应性和哮喘中嗜酸性粒细胞炎症的病理生理中起核心作用。了解消除IL-5受体(IL-5R)诱导的炎症信号的机制对于开发调节IL-5介导的炎症的新方法具有重要意义。本应用程序的目的是确定通过泛素和蛋白酶体降解途径控制IL-5R内化的分子机制。我们的总体假设是,il -5诱导的IL-5R内化受到两种不同机制的调节:泛素/蛋白酶体降解途径和网格蛋白介导的内吞作用。目的1。验证蛋白酶体通过首先降解(c)细胞质结构域介导连接的IL-5R内化的假设。为了确定部分(c)胞质结构域的降解是否是IL-5R内化的起始信号,将检查各种细胞质截断的(c)突变体介导连接的IL-5R的蛋白酶体非依赖性内化的能力。此外,还将研究其他参与c的细胞因子IL-3和GM-CSF对c内化过程中蛋白酶体活性的要求。目标2。验证IL-5R通过网格蛋白介导的内吞作用内化的假设,并且受体的内化发生在蛋白酶体降解(c)细胞质结构域之前。将使用两种不同的方法来抑制网格蛋白介导的内吞作用,以确定IL-5R是否通过这种机制内化,以及il -5刺激的c信号传导和蛋白酶体降解是否在IL-5R内化后发生。目标3。探讨c泛素化在IL-5R内化中的功能作用和性质。温度敏感的ts20细胞系在泛素结合上有温度敏感缺陷,(c突变体在所有形式的泛素化上都有缺陷,以及显性的阴性泛素异构体将被用来研究(c泛素化在IL-5R内吞作用中的作用和性质。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAGARITA MARTINEZ-MOCZYGEMBA其他文献
MAGARITA MARTINEZ-MOCZYGEMBA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAGARITA MARTINEZ-MOCZYGEMBA', 18)}}的其他基金
Proteasome Regulation of Interleukin-5 Receptor Endocyt*
Interleukin-5 受体内吞细胞的蛋白酶体调节*
- 批准号:
6948288 - 财政年份:2004
- 资助金额:
$ 30.18万 - 项目类别:
Proteasome Regulation of Interleukin-5 Receptor Endocytosis
Interleukin-5 受体胞吞作用的蛋白酶体调节
- 批准号:
7195020 - 财政年份:2004
- 资助金额:
$ 30.18万 - 项目类别:
Proteasome Regulation of IL-5 Receptor Endocytosis
IL-5 受体胞吞作用的蛋白酶体调节
- 批准号:
6861635 - 财政年份:2004
- 资助金额:
$ 30.18万 - 项目类别:
Proteasome Regulation of Interleukin-5 Receptor Endocyt*
Interleukin-5 受体内吞细胞的蛋白酶体调节*
- 批准号:
7020698 - 财政年份:2004
- 资助金额:
$ 30.18万 - 项目类别:
Regulation of Interleukin-5 Receptor Signaling
IL-5 受体信号传导的调节
- 批准号:
6416767 - 财政年份:2002
- 资助金额:
$ 30.18万 - 项目类别:
Regulation of Interleukin-5 Receptor Signaling
IL-5 受体信号传导的调节
- 批准号:
6650360 - 财政年份:2002
- 资助金额:
$ 30.18万 - 项目类别:
相似海外基金
Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
- 批准号:
2901112 - 财政年份:2024
- 资助金额:
$ 30.18万 - 项目类别:
Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
- 批准号:
485504 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
- 批准号:
495593 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
- 批准号:
493135 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
- 批准号:
493526 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
- 批准号:
10723233 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
- 批准号:
10723861 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
- 批准号:
10586398 - 财政年份:2023
- 资助金额:
$ 30.18万 - 项目类别: